FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
28 févr. 2022 16h01 HE
|
FibroGen, Inc.
Completed enrollment in LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer Completed enrollment in LELANTOS-1 Phase 3 study of pamrevlumab in Duchenne muscular...
FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
20 déc. 2021 08h00 HE
|
FibroGen, Inc.
Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment, potential milestones...